Where Global Innovation
and Capital Meet
Sectors Art of CVCConsumerEnergyFinancialHealthIndustrialITMediaServicesStartupsTelecomsTransportUniversity

Health

Transcarent takes in $200m

Rush University Medical Center is among the backers of Transcarent’s series C round, which pushed the company’s overall financing to $298m.


Jan 13, 2022

Roche rounds up $290m for Freenome

The diagnostics technology developer has raised another $290m from existing investor Roche, which will support it as it looks to expand its products to additional cancers.

Jan 13, 2022

Daily Deal Round Up: January 12, 2022

Synthetic DNA producer DNA Script and personalised health plan provider Transcarent each closed $200m corporate-backed series C rounds.

Jan 12, 2022

Deals: January 12, 2022

Every day, Global University Venturing rounds up investments from across the university innovation ecosystem in its deal net.

Jan 12, 2022

Daily Deal Round Up: January 11, 2022

Business-focused neobank Qonto raised $552m from investors including Tencent at a $552m valuation while SK provided $350m for Center for CDMO Breakthrough Medicines.

Jan 11, 2022

Deals: January 11, 2022

Every day, Global University Venturing rounds up investments from across the university innovation ecosystem in its deal net.

Jan 11, 2022

Eikon excels at $518m series B

Eikon Therapeutics was co-founded by UC Berkeley researchers, one of whom has already received a Nobel Prize for the underlying technology.

Jan 11, 2022

Daily Deal Round Up: January 10, 2022

Raw materials provider Vital Thin Film secured $188m in a round co-led by BYD while drug developers CinCor and Vigil raised a total of $292m in their initial public offerings.

Jan 10, 2022

Exits: January 10, 2022

A roundup of exits, including IPOs and acquisitions, across the tech transfer ecosystem.

Jan 10, 2022

Deals: January 10, 2022

Every day, Global University Venturing rounds up investments from across the university innovation ecosystem in its deal net.

Jan 10, 2022

Korro Bio concludes $116m series B

All existing shareholders including Alexandria Venture Investments contributed to the RNA drug developer’s series B round, following a $91.5m series A in mid-2020.

Jan 10, 2022
© 2026 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here